Published • loading... • Updated
Novo Records a Surge in Ozempic Sales in India (NVO:NYSE)
Pharmarack said sales rose 40% in April as lower prices improved affordability and helped Novo Nordisk defend share against cheaper GLP-1 rivals.
Summary by Seeking Alpha
3 Articles
3 Articles
Novo Nordisk's Ozempic India Price Cut Boosts Obesity Drug Sales
(Bloomberg) — Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.
·Canada
Read Full Article
Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
(Bloomberg) -- Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.
·Bern, Switzerland
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left1Leaning Right2Center0Last UpdatedBias Distribution67% Right
Bias Distribution
- 67% of the sources lean Right
67% Right
L 33%
R 67%
Factuality
To view factuality data please Upgrade to Premium
